

CMC STRATEGY FORUM

ADVANCING BIOPHARMACEUTICAL DEVELOPMENT

EUROPE 2022

KNOWLEDGE SHARING AND CAPACITY BUILDING

- The *importance of mass spectrometry* in the CMC field was never a consideration before now.
- *Innovative ideas* from the past are being revived and examined.
- *Progress is occurring – interactions are increasing* on both sides with industry representatives and regulators.
- The environment presented a *familiar and open platform with ample conversations* between companies and regulators to promote the sharing of information.

CMC STRATEGY FORUM EUROPE 2022 BY THE NUMBERS



Attendee Participants

In-Person - **135**

Virtual - **46**

First Time - **69**



Regulators Participation

24



Company Participation

44



Country Participation

17

Austria | Belgium | Denmark | Estonia | Finland |
France | Germany | Ireland | Israel | Netherlands |
Norway | Slovenia | South Korea | Sweden |
Switzerland | United Kingdom | United States